177 related articles for article (PubMed ID: 34288884)
1. Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma.
Greenman Y; Bronstein MD
Eur J Endocrinol; 2021 Aug; 185(4):D11-D20. PubMed ID: 34288884
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.
Batista RL; Musolino NRC; Cescato VAS; da Silva GO; Medeiros RSS; Herkenhoff CGB; Trarbach EB; Cunha-Neto MB
Am J Clin Oncol; 2019 Feb; 42(2):221-227. PubMed ID: 30540568
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas.
Ayalon-Dangur I; Turjeman A; Hirsch D; Robenshtok E; Tsvetov G; Gorshtein A; Masri H; Shraga-Slutzky I; Manisterski Y; Akirov A; Shimon I
Pituitary; 2024 Feb; 27(1):52-60. PubMed ID: 38064148
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience.
Vargas-Ortega G; González-Virla B; Balcázar-Hernández L; Arreola-Rosales R; Benitez-Rodríguez FJ; López Félix B; Mercado M
Arch Endocrinol Metab; 2022 Sept 08; 66(4):506-511. PubMed ID: 35758837
[TBL] [Abstract][Full Text] [Related]
5. The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA; Ioachimescu AG
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
[TBL] [Abstract][Full Text] [Related]
6. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
[TBL] [Abstract][Full Text] [Related]
7. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
8. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
Iglesias P; Biagetti B; Araujo-Castro M; Alcázar V; Guerrero-Pérez F; Rivero N; Casteràs A; Gómez CG; Izquierdo BG; Torres VV; Pascual-Corrales E; Pavón I; Villabona C; Cordido F; Díez JJ
J Neurooncol; 2022 Nov; 160(2):351-359. PubMed ID: 36355257
[TBL] [Abstract][Full Text] [Related]
9. Optimal management of non-functioning pituitary adenomas.
Greenman Y; Stern N
Endocrine; 2015 Sep; 50(1):51-5. PubMed ID: 26179179
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the outcome of microsurgical transsphenoidal surgery for pituitary adenomas: a study on 184 patients.
Lampropoulos KI; Samonis G; Nomikos P
Hormones (Athens); 2013; 12(2):254-64. PubMed ID: 23933694
[TBL] [Abstract][Full Text] [Related]
11. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy for non-functioning pituitary tumors-a critical approach.
Tampourlou M; Karapanou O; Vassiliadi DA; Tsagarakis S
Hormones (Athens); 2019 Jun; 18(2):117-126. PubMed ID: 30368687
[TBL] [Abstract][Full Text] [Related]
13. Clinical and epidemiological characteristics of pituitary tumours in a single centre in Saudi Arabia.
Hussein SH; Wahedi TS; Johani NA; Hakami YA; Alzahrani K; AlMalki MH
Hormones (Athens); 2018 Jun; 17(2):261-267. PubMed ID: 29858852
[TBL] [Abstract][Full Text] [Related]
14. Non-functioning pituitary macroadenomas: Benefit from early growth hormone substitution after surgery.
Sauer N; Flitsch J; Doeing I; Dannheim V; Burkhardt T; Aberle J
Growth Horm IGF Res; 2014; 24(2-3):71-5. PubMed ID: 24726277
[TBL] [Abstract][Full Text] [Related]
15. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors.
Ferrante E; Ferraroni M; Castrignanò T; Menicatti L; Anagni M; Reimondo G; Del Monte P; Bernasconi D; Loli P; Faustini-Fustini M; Borretta G; Terzolo M; Losa M; Morabito A; Spada A; Beck-Peccoz P; Lania AG
Eur J Endocrinol; 2006 Dec; 155(6):823-9. PubMed ID: 17132751
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Treatment of Non-Functioning Pituitary Adenomas.
Vargas-Ortega G; Gonzalez-Virla B; Romero-Gameros CA
Arch Med Res; 2023 Dec; 54(8):102917. PubMed ID: 37996269
[TBL] [Abstract][Full Text] [Related]
17. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.
Losa M; Mortini P; Barzaghi R; Ribotto P; Terreni MR; Marzoli SB; Pieralli S; Giovanelli M
J Neurosurg; 2008 Mar; 108(3):525-32. PubMed ID: 18312100
[TBL] [Abstract][Full Text] [Related]
18. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
[TBL] [Abstract][Full Text] [Related]
19. Ectopic pituitary adenomas: common presentations of a rare entity.
Agely A; Okromelidze L; Vilanilam GK; Chaichana KL; Middlebrooks EH; Gupta V
Pituitary; 2019 Aug; 22(4):339-343. PubMed ID: 30895500
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic Endonasal Approach to Giant Pituitary Adenomas: Surgical Outcomes and Review of the Literature.
Rahimli T; Hidayetov T; Yusifli Z; Memmedzade H; Rajabov T; Aghayev K
World Neurosurg; 2021 May; 149():e1043-e1055. PubMed ID: 33524611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
